Table 1.
Subgroup analysis of the effects of resveratrol on glioma growth.
| Variable | Fold Increase | |||
|---|---|---|---|---|
| No. of Studies | WDM (95% CI) |
p-Value | I2 (%) | |
| Animal model | ||||
| Heterotopic | 8 | −2.179 (−3.707 to −0.652) | 0.005 * | 85.56 |
| Orthotopic | 2 | −2.580 (−5.846 to 0.686) | 0.122 | 88.79 |
| Chi2 = 0.047; p-value = 0.828 | ||||
| Cells | ||||
| Human | 8 | −1.794 (−2.917 to 0.670) | 0.002 * | 86.01 |
| Animal | 2 | −5.678 (−10.098 to −1.258) | 0.012 * | 80.02 |
| Chi2 = 2.786; p-value = 0.095 | ||||
| Intervention duration (days) | ||||
| 10–14 | 5 | −0.954 (−1.983 to 0.075) | 0.069 | 74.80 |
| 18–30 | 5 | −3.778 (−5.312 to −2.243) | <0.001 * | 69.36 |
| Chi2 = 9.778; p-value = 0.008 * | ||||
| Administration mode | ||||
| Intraperitoneal | 8 | −1.140 (−2.079 to −0.200) | 0.017 * | 73.27 |
| Intravenous | 1 | −4.272 (−8.167 to −0.377) | 0.032 * | 0 |
| Oral | 1 | −4.404 (−6.481 to −2.327) | <0.001 * | 0 |
| Chi2 = 9.484; p-value = 0.009 * | ||||
| Mean daily dose (mg/kg) | ||||
| 0.013–6 | 2 | −1.340 (−4.607 to 1.327) | 0.421 | 84.71 |
| 6.1–15 | 5 | −1.891 (−4.217 to 0.436) | 0.111 | 0 |
| 15.1–150 | 3 | −3.184 (−6.596 to −1.032) | 0.007 * | 93.91 |
| Chi2 = 1.755; p-value = 0.635 | ||||
WDM—weighted difference in mean; CI—confidence interval; * indicates a significant result.